Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | CPA1 | P15085 | 3/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070175 | 1.00 | FPR2 (0.49) | FPR2MMEALDH1A1ALOX15ACE | |
| SCHEMBL1070143 | 1.00 | FPR2 (0.49) | FPR2MMEALDH1A1ALOX15ACE | |
| SCHEMBL1070178 | 1.00 | FPR2 (0.49) | FPR2MMEALDH1A1ALOX15ACE | |
| SCHEMBL25265326 | 1.00 | FPR2 (0.49) | FPR2MMEALDH1A1ALOX15ACE | |
| SCHEMBL1070147 | 1.00 | FPR2 (0.49) | FPR2MMEALDH1A1ALOX15ACE | |
| SCHEMBL22290251 | 0.95 | HDAC3 (0.44) | FPR2MMEALDH1A1ALOX15ACE | |
| SCHEMBL1071712 | 0.95 | HDAC3 (0.44) | FPR2MMEALDH1A1ALOX15ACE | |
| SCHEMBL1070478 | 0.91 | OPRK1 (0.58) | ALDH1A1OPRK1 | |
| SCHEMBL1069413 | 0.91 | OPRK1 (0.58) | ALDH1A1OPRK1 | |
| SCHEMBL1067140 | 0.89 | TACR1 (0.51) | MMEALDH1A1ACEOPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | claimed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | claimed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | claimed |
| WO-2022190100-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2022-09-15 | — | — | WO | claimed |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | NEURODERM LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| EP-4460289-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | Neuroderm, Ltd. (IL) | 2024-11-13 | — | — | EP | disclosed |
| CN-118765198-A | Methods and compositions for treating parkinson's disease | 纽罗德姆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | NEURODERM, LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| WO-2022190100-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | FPR2 3945/4885MME 218/4885ALDH1A1 609/4885 |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | FPR2 3927/4885MME 1412/4885ALDH1A1 398/4885 |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | DDC, DDT, COMT | FPR2 3903/4885MME 212/4885ALDH1A1 647/4885 |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | DDC, COMT, DDT | FPR2 4047/4885MME 344/4885ALDH1A1 547/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | FPR2 3895/4885MME 203/4885ALDH1A1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.